Assays - Acyclovir1

Pharmacokinetics and Bioavailability of Different Formulations of Aciclovir

Author: H. Vergin, H.J. Mascher, R. Metz
Publisher: Drug Research, 45 (1995), 508 - 515

The pharmacokinetics and bioavailability of aciclovir (CAS 59277-89-3) were examined after administration of newly developed 200 mg and 400 mg tablets. Two studies, each with 24 subjects of either sex, were performed. In the three-way study I, two different tablets containing 200 mg of aciclovir (test and reference products) and a short infusion of 250 mg aciclovir were compared. In the two-way study II, the bioequivalence of a newly developed 400 mg aciclovir tablet was tested against a standard product.

New, high-sensitivity high-performance liquid-chromatographic method for the determination of Acyclovir in human plasma, using fluorimetric detection

Author: H.J. Mascher, C. Kikuta, R. Metz, H. Vergin
Publisher: J. Chromatogr., 583 (1992), 122-127

A high-performance liquid chromatographic method for the determination of acyclovir in human plasma has been developed. It is the first published chromatographic method capable of determining acyclovir in plasma with sufficient sensitivity and for sufficiently long periods of time following oral administration of a standard dose of acyclovir during pharmacokinetic investigations. Following precipitation of the proteins with perchloric acid, the sample is chromatographed with a strongly acidic mobile phase on a reversed-phase column, and is then subjected to fluorometric detection (excitation 260 nm, emission 375 nm). The determination limit is 6 - 10 ng/ml human plasma. The calibration is linear in the range of 10 - 12400 ng/ml plasma, with the coefficients of variation less than 8 %. the absolute recovery rate is between 102 and 113 %. This method has already been used to analyse several thousand plasma samples.